# Genenta Science S.p.A. (GNTA)

> Source: Nexqual · https://nexqual.com/GNTA · data as of 2026-10-23 20:00 UTC · cite as "Nexqual, Genenta Science S.p.A. (GNTA), nexqual.com/GNTA" · informational, not investment advice.

**Price:** USD 0.63 (-0.02% on the day) · last close of Oct 23, 2026; US market closed, not a live price. Prev close 0.63 · day 0.63–0.64 · 52w 0.55–10 · market cap $30.4M · NCM

## Key facts
- Analysts: None.
- Total return with dividends: 1Y -89.8% vs S&P 500 +14.0%; 5Y -94.3% vs S&P 500 +76.9%.

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-24) | 5Y (from 2021-12-13) |
|---|---|---|
| Total return | -89.8% | -94.3% |
| S&P 500 (SPY) | +14.0% | +76.9% |
| Per year | -90.0% | -44.5% |
| Volatility (annualized) | 136.6% | 97.1% |
| Max drawdown | -90.7% (Oct 2025→May 2026) | -95.1% (Dec 2021→May 2026) |

## Peers (Conglomerates)
VMI (Valmont Industries, Inc.) USD 435.01 -0.20% · HON (Honeywell International Inc.) USD 221.15 +1.30% · MMM (3M Company) USD 173.46 -1.20% · CNI (Canadian National Railway Compa) USD 123.15 -1.42% · VRT (Vertiv Holdings, LLC) USD 194.32 -0.65% · NOC (Northrop Grumman Corporation) USD 551.44 -0.16%

## More
Full page: https://nexqual.com/GNTA · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in GNTA's own 20-F filed 2026-04-01 (https://www.sec.gov/Archives/edgar/data/1838716/000149315226014387/form20-f.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | AGC Biologics | "have entered into agreements with AGC Biologics to manufacture our LVV and certain drug products for our ongoing clinical programs in" |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends 2026-12-31) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |